ClinicalTrials.gg
RecruitingNCT07150806Updated Aug 13, 2026

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

A Phase 1/2 interventional study of Actinium Ac 225 DOTATATE RYZ101 and Biospecimen Collection in Recurrent Meningioma, sponsored by Joshua Palmer. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Joshua Palmer · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 129 studies in Meningioma with a site in United States — 27 open to participants now, 39 under way, 1 of them phase 3. Meningioma · United States.

Planned enrollment
52nd of 107
30 · median 30
Started
2025
with 5 others
Phase 1/2
9 of 129
3 open now
Primary completion
2026-12
later than 5 of 37 live
Registered
124th of 129
by date

Among the 129 studies in Meningioma with a site in United States, this one is the 52nd largest by planned enrollment of the 107 interventional ones that give a count, is one of 6 that started in 2025, is one of 9 in phase 1/2, reaches primary completion later than 5 of the 37 other live ones, and was the 124th registered.

Meningioma

256 studies on the registry are indexed under Meningioma; 86 are open to participants now.

Browse Meningioma studies →

Open to participants now

27 of the 129 studies in Meningioma with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Meningioma studies recruiting now, 43 (65%) set no upper age limit and 9 (14%) stop at 75 or younger; 8 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 129 studies in Meningioma with a site in United States, or all of them as a file.
02

Study summary

This phase I/II tests the safety, side effects, best dose and how well giving RYZ101 works for the treatment of patients with intracranial meningioma that is growing, spreading, or getting worse (progressive) or that has come back after a period of improvement (recurrent). RYZ101 is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177-dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving RYZ101 may be safe, tolerable and/or effective in treating patients with progressive or recurrent intracranial meningioma.

Read the detailed description

PRIMARY OBJECTIVE:

I. To estimate the efficacy of 225Ac-DOTATATE (RYZ101) therapy in the treatment of patients with progressive or recurrent grade 1-3 intracranial meningioma as measured by the progression free survival at 6 months.

SECONDARY OBJECTIVES:

I. To evaluate the objective response rate (ORR) by standard of care brain magnetic resonance imaging (MRI) at 6 months and gallium Ga 68-DOTATATE (68Ga-DOTATATE) positron emission tomography (PET) imaging at 1 year.

II. To determine the overall survival (by grade cohort) in patients with progressive / recurrent meningioma during or after treatment with RYZ101.

III. To determine the progression-free survival (by grade cohort) in patients with progressive / recurrent meningioma during or after treatment with RYZ101.

IV. To determine the toxicity rate in patients with progressive / recurrent meningioma during or after treatment with RYZ101.

V. To perform semiquantitative analysis of PET standardized uptake value (SUV) uptake and compare to the background for treatment response assessment and as a potential biomarker of response and prognosis.

OUTLINE:

Patients receive RYZ101 intravenously (IV) and amino acids, with L-arginine and L-lysine, IV on day 1 of each cycle. Cycles repeat every 8 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients receive Ga 68-DOTATATE IV and undergo PET scan or somatostatin receptor (SSTR) PET scan, computed tomography (CT) scan, MRI and undergo blood and urine sample collection and may undergo echocardiography or multigated acquisition (MUGA) scan throughout the study.

After completion of study treatment, patients are followed up every 3 months for 1 year.

03

Conditions studied

  • Recurrent Meningioma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients of age > 18 years
  • Patients with 68Ga-DOTATATE positive recurrent or progressive meningiomas, any World Health Organization (WHO) grade, who have progressed after treatment.

    • For Grade I meningioma, patients must have either:

      • Progressive disease after at least surgical resection and radiotherapy, as defined as an increase in size of the measurable primary lesion on imaging by 25% or more between scans separated by no more than 12 months; or
      • Progressive residual tumor after maximal safe resection, located at or near critical organs at-risk and considered to be high-risk for radiation injury by the treating investigator. Prior external beam radiotherapy is not required for these subjects.
    • For Grade II or III meningioma, subjects must have either:

      • Progressive disease after at least surgical resection and radiotherapy, as defined as an increase in size of the measurable primary lesion on imaging by 25% or more between scans separated by no more than 12 months or
      • Residual after prior surgery without requirement of progression, or
      • Unsuitable for, or decline other standard of care treatment.
  • Positive 68Ga-DOTATATE uptake on PET/CT at baseline, defined as target lesion uptake higher than the background
  • Presence of measurable disease defined as at least one lesion measuring ≥ 5 mm in at least one dimension by contrast-enhanced MRI performed within 30 days prior to study registration
  • Multifocal disease allowed but limited to the physician discretion for safety (ie. large mass effect or damage to nearby critical organs with prior radiation treatment.)
  • There is no limit on the number of prior surgeries, radiation therapy, radiosurgery, systemically administered therapeutic agents or theranostic agents
  • For patients treated with external beam radiation, interstitial brachytherapy or radiosurgery, an interval ≥ 24 weeks must have elapsed from completion from these therapies to registration
  • An interval of ≥ 28 days (or 5 half-lives, whichever is shorter) from prior cytotoxic chemotherapy (6 weeks from nitrosoureas), biologic agent, agent or any other systemic agent prescribed for the purpose of treating meningioma
  • An interval of ≥ 28 days from craniotomy and ≥ 7 days from stereotactic
  • Patients must be willing and able to undergo regular MRI scans of the brain
  • Patients must have recovered to (CTCAE) grade ≤ 1 or pretreatment baseline from adverse events related to prior therapy (exclusions include alopecia, laboratory values listed per inclusion criteria, lymphopenia, sensory neuropathy ≤ grade 2, or other ≤ grade 2 not constituting a safety risk based on the investigator's judgment)
  • Any neurological symptoms must be stable for at least 28 days prior to enrollment and patients should not require escalating doses of to control neurological symptoms (stable low dose maintenance steroids at ≤ 8 mg dexamethasone or equivalent are allowed)
  • Sufficient renal function, as evidenced by (CrCl) ≥ 60 mL/min or ≥60 mL/min/1.73m2 calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
  • concentration ≥ 5.0 mmol/L (≥ 8.0 g/dL)

    • Note: Colony-stimulating factors, -production stimulators and/or transfusions within 4 weeks prior to screening and first dose of study treatment are not permitted to meet these criteria
  • (ANC) ≥ 1000 cells/µL (≥ 1000 cells/mm\^3)

    • Note: Colony-stimulating factors, platelet-production stimulators and/or transfusions within 4 weeks prior to screening and first dose of study treatment are not permitted to meet these criteria.
  • Platelets > 100 × 10\^9/L (100 × 10\^3/mm\^3)

    • Note: Colony-stimulating factors, platelet-production stimulators and/or transfusions within 4 weeks prior to screening and first dose of study treatment are not permitted to meet these criteria.
  • (AST) and alanine aminotransferase (ALT) ≤ 2.5 × (ULN) (or ≤ 5 × ULN if presence of liver )
  • Total ≤ 3 × ULN
  • Serum albumin ≥ 3.0 g/dL
  • Adequate coagulation function, defined by (INR) or prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN, unless subject is receiving anticoagulant therapy and PT or aPTT is within therapeutic range of intended use of anticoagulants
  • For women of (WOCBP):

    • Negative pregnancy test within 48 hours prior to the first dose of study treatment
    • Agreement to use barrier and a second form of highly effective contraception while receiving study treatment and for 7 months following their last dose of study treatment. Alternatively, total abstinence is also considered a highly effective contraception method when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.

A woman is considered to be of childbearing potential if she is postmenarche, has not reached a state (≥ 12 continuous months of amenorrhea [no menstrual bleeding of any kind, including menstrual period, irregular bleeding, spotting, etc.] with no identified cause other than menopause), and has not undergone surgical sterilization (total hysterectomy, or bilateral tubal ligation or bilateral oophorectomy at least 6 weeks before first dose of study treatment)

  • Sexually active male subjects must use a condom during intercourse while receiving RYZ101 and for at least 120 days after the last dose of the study treatment and should not father a child during this period.

    • Male study subjects whose sexual partners are WOCBP must also agree to use a second form of highly effective contraception while receiving RYZ101 and for at least 4 months following their last dose. Alternatively, total abstinence is also considered a highly effective contraception method when this is in line with the preferred and usual lifestyle of the subject.
    • Vasectomized men are also required to use a condom during intercourse, including with a male partner, to prevent delivery of the drug via seminal fluid.
  • The subject, or their legally authorized representative, must provide

Exclusion criteria

Exclusion Criteria:

  • (ECOG) performance status > 2
  • Received radiation therapy to the brain in last 24 weeks
  • History of or allergy to Actinium Ac-225 (225Ac), Gallium Ga 68 (68Ga), Copper Cu 64 (64Cu), octreotate, or any of the of DOTATATE imaging agents
  • Prior alpha radiopharmaceutical therapies (RPT), including radioembolization
  • Prior solid organ or bone marrow transplantation
  • Significant cardiovascular disease, defined as:

    • (NYHA) Class ≥ II heart failure.
    • Known (LVEF) \< 50%.
    • History of myocardial infarction, acute coronary syndrome, or coronary angioplasty/stenting/bypass within the last 6 months.
    • corrected for heart rate using Fridericia's formula (QTcF) > 470 ms, demonstrated by the average value of 3 consecutive (ECGs).
    • Resistant hypertension, defined as persistent uncontrolled blood pressure (BP) > 140/90 mmHg while on optimal doses of at least 3 antihypertensive medications with 1 being a diuretic. Patients with baseline hypertension may be eligible after initiation of antihypertensive therapy
  • Uncontrolled diabetes mellitus as defined by (HgB A1c) > 8% in patients with known diagnosis of diabetes mellitus)
  • Liver cirrhosis or liver transplantation
  • Pregnancy or lactation
  • Subject, or their legally authorized representative, unable to understand or unwilling to sign an Institutional review board approved written document
  • Current somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Treatment (RYZ101)

    Patients receive RYZ101 IV and amino acids, with L-arginine and L-lysine, IV on day 1 of each cycle. Cycles repeat every 8 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients receive gallium Ga 68-DOTATATE IV and undergo PET scan or SSTR PET scan, CT scan, MRI and undergo blood and urine sample collection and may undergo echocardiography or MUGA scan throughout the study.

    Drug: Actinium Ac 225 DOTATATE RYZ101 · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Procedure: Echocardiography Test · Radiation: Gallium Ga 68-DOTATATE · Drug: L-lysine/L-arginine-containing Amino Acid · Procedure: Magnetic Resonance Imaging · Procedure: Multigated Acquisition Scan · Procedure: Positron Emission Tomography · Procedure: Somatostatin Receptor Positron Emission Tomography

Interventions

  • DrugActinium AC-225 dotatateStudies of Actinium AC-225 dotatateActinium AC-225 dotatate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: 225Ac-DOTA-TATE RYZ101, 225Ac-Oxodotreotide, Actinium Ac 225-Dotatate RYZ101, ACTINIUM AC-225 DOTATATE, RYZ 101, RYZ-101, RYZ101

  • ProcedureBiospecimen Collection

    Undergo blood and urine sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • ProcedureComputed Tomography

    Undergo CT scan

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography

  • ProcedureEchocardiography Test

    Undergo echocardiography

    Also known as: EC, Echocardiography

  • RadiationGallium Ga 68-DOTATATE

    Given IV

    Also known as: (68)Ga-DOTA-TATE, 68Ga-DOTA-0-Tyr3-Octreotate, 68Ga-DOTATATE, Gallium Ga 68 Oxodotreotide, Gallium Oxodotreotide Ga-68, Gallium-68 DOTA-DPhe1, Tyr3-octreotate

  • DrugL-lysine/L-arginine-containing Amino Acid

    Given IV

    Also known as: Amino Acid Renal Protectant Solution, Amino Acid Solution-containing L-lysine and L-arginine, Intravenous L-lysine/L-arginine-containing Amino Acid Solution, L-lysine/L-arginine AA Solution, Lysine-Arginine Amino Acid Solution, Lysine/Arginine Amino Acid Solution, Radioprotective Amino Acid Solution

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • ProcedureMultigated Acquisition Scan

    Undergo MUGA scan

    Also known as: Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning

  • ProcedurePositron Emission Tomography

    Undergo PET scan

    Also known as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT

  • ProcedureSomatostatin Receptor Positron Emission Tomography

    Undergo SSTR PET scan

    Also known as: SSTR-PET

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS)

    Defined as survival without progression of disease (progressive disease, based on Response Assessment in Neuro-Oncology Criteria \[RANO\] 2.0 criteria) or death. Kaplan-Meier analyses will be used to estimate PFS.

    Time frame: At 6 months

Secondary outcomes

  1. Objective response rate (ORR)

    Assessed by standard of care brain magnetic resonance imaging (MRI) at 6 months and gallium Ga 68-DOTATATE positron emission tomography (PET) at 1 year. ORR defined as the best response including complete response, partial response or stable disease per RANO 2.0 criteria.

    Time frame: At 6 months and 1 year

  2. Overall survival (OS)

    Kaplan-Meier analyses will be used to estimate OS.

    Time frame: From the date of trial enrolment to date of death, up to 2 years

  3. Incidence of adverse events

    The number and type of adverse events will be summarized, using the NCI's Common Toxicity Criteria for Adverse Events, version 5.0 (CTCAE V.5.0).

    Time frame: Up to 2 years

  4. PET standardized uptake value uptake

    To compare to the background for treatment response assessment and as a potential biomarker of response and prognosis.

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2025
First posted
Sep 2, 2025
StartActual
Nov 12, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07150806
Lead sponsor
Joshua Palmer
Collaborators
RayzeBio, Inc.
Responsible party
Joshua Palmer (Principal Investigator, Ohio State University Comprehensive Cancer Center) — Sponsor-investigator
First posted
Sep 2, 2025
Start date
Nov 12, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 13, 2026

Study contacts

Central Nervous System Research Team
Contact
_CNSCRCs_@osumc.edu
614-293-9974
The Ohio State University Comprehensive Cancer Center
Contact
OSUCCCClinicaltrials@osumc.edu
800-293-5066
Joshua D Palmer, MD
principal investigator · Ohio State University Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Actinium AC-225 dotatate

Start the discussion